Six month report January-June 2001

Six month report January-June 2001: Continued good growth and geographical market expansion Total revenues for the period increased by 22% (9%*) to SEK 12,799 M (10,514). Operating earnings, EBITDA, amounted to SEK 2,122 M (SEK 1,194 M incl. non-recurring items) corresponding to a margin of 16.6% (9.3% incl. non-recurring items). Earnings per share decreased by 36% to SEK 0.45 (-1.19 incl. non-recurring items) and cash earnings per share increased by 7% to SEK 4.26 (2.62 incl. non-recurring items). Second quarter group revenues increased to SEK 6,619 M (5,400) including a continued good revenue growth momentum of 23% (9%*). Gambro Healthcare expanded revenues by 28% (12%*) - in second quarter by 30% (13%*). Important clinics acquisitions and de novo development in the US, Latin America and Europe, reaching 50,000 patients in total. In the US provisions of USD 85 M (SEK 927 M) for unbilled laboratory receiv ables. A government subpoena received for documentation on Gambro Healthcare. Continued good sales growth, 15% (7%*) for Gambro Renal Products - second quarter 14% (4%*) - including good development in Europe and the Americas. New products rolled out. Good sales development for Gambro BCT, +23% (10%*) - second quarter +25% (12%*). Strong growth in the US. Blood bank product offering broadened by acquisition of Sanguistech (after period). Pathogen Eradication Technology (PET) process receives broad US patent approval (after period). *) currency adjusted For further information please contact: Lars Granlöf, Senior Vice President, CFO, +46-8-613 65 00, +46-70-513 65 48 Bengt Modéer, Senior Vice President, Investor Relations, tel. +46-8-613 65 00, +46-70-513 65 33 Kevin Smith, President Gambro Inc., Investor Relations US, tel. +1-303 231 4750 Gambro's financial information is also available on the Internet: ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: Full Report Full Report

About Us

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.